Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Novel agents: clinical trial design.

A R Tan1, S M Swain

  • 1Cancer Therapeutics Branch, National Cancer Institute, Bethesda, MD 20889, USA.

Seminars in Oncology
|November 14, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tumor-infiltrating lymphocytes in HER2-positive breast cancer: potential impact and challenges.

ESMO open·2025
Same author

Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2-positive early breast cancer (EBC).

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Optimal adjuvant therapy in older (≥70 years of age) women with low-risk early-stage breast cancer.

NPJ breast cancer·2023
Same author

Patient-reported outcomes predict survival and adverse events following anticancer treatment initiation in advanced HER2-positive breast cancer.

ESMO open·2022
Same author

Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study.

Breast cancer research and treatment·2019
Same journal

A systematic scoping review of cancer-related anemia treatment: Comparative trial outcomes, current guidelines, and future perspectives.

Seminars in oncology·2026
Same journal

Steroid-induced tumor lysis syndrome in solid tumors: A case report and review of the literature.

Seminars in oncology·2026
Same journal

PSMA PET/CT staging in intermediate-risk prostate cancer: Toward risk-adapted implementation.

Seminars in oncology·2026
Same journal

Angiogenesis and the corresponding antiangiogenic therapy in gastroenteropancreatic neuroendocrine neoplasms.

Seminars in oncology·2026
Same journal

Post-translational regulation of steroidogenesis and its clinical relevance in hormone responsive cancers.

Seminars in oncology·2026
Same journal

Physics-informed machine learning for tumor microenvironment-responsive nanomedicine: Recent updates.

Seminars in oncology·2026
See all related articles

Developing targeted anticancer drugs offers promise but faces challenges. This study outlines optimal methods for evaluating these novel molecularly targeted anticancer agents and their clinical trial designs.

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Background:

  • Molecularly targeted anticancer agents represent a significant advancement in cancer therapy.
  • Evaluating the efficacy and safety of these novel drugs presents unique challenges for researchers.

Purpose of the Study:

  • To provide an overview of the difficulties in developing targeted anticancer agents.
  • To describe optimal clinical research methodology for determining the efficacy of these compounds.

Main Methods:

  • Review of challenges in preclinical model creation for target assessment.
  • Discussion on validation of surrogate endpoints for novel anticancer drugs.
  • Analysis of effective clinical trial designs for targeted therapies.

Related Experiment Videos

Main Results:

  • Identified key challenges in evaluating molecularly targeted anticancer agents.
  • Highlighted the need for appropriate models and validated surrogate endpoints.
  • Emphasized the importance of effective clinical trial designs.

Conclusions:

  • Overcoming evaluation challenges is crucial for advancing targeted anticancer drug development.
  • Optimal clinical research methodology is essential for accurately determining drug efficacy.
  • This work provides a framework for future research in targeted cancer therapy evaluation.